AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3605563
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml 25% cocaine HCl combined with 0.1% adrenaline in paraffin paste
Trial: 3605563
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml 25% cocaine HCl in paraffin paste
Trial: 3605563
Drug: 4.0 ml
RxNorm normalized name: OCTINOXATE 7.5 mL in 100 mL / OCTISALATE 4.0 mL in 100 mL TOPICAL LIQUID [LONG LAST GLOSSWEAR SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 ml aqueous 4% cocaine HCl combined with 0.05% adrenaline
Trial: 3605563
Drug: 4.0 ml
RxNorm normalized name: OCTINOXATE 7.5 mL in 100 mL / OCTISALATE 4.0 mL in 100 mL TOPICAL LIQUID [LONG LAST GLOSSWEAR SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 ml aqueous 4% cocaine HCl on ribbon gauze
Trial: 27130202
Drug: Ipratropium bromide/albuterol
RxNorm normalized name: ipratropium bromide/albuterol sulfate 0.5 mg-2.5 mg/2.5 mL INHALATION VIAL, NEBULIZER (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide/albuterol (CVT-MDI)
Trial: 27130202
Drug: Albuterol (ALB-HFA)
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (ALB-HFA)
Trial: 24465438
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins (0.56 mg 5‐methyl‐tetrahydrofolate, 3 mg vitamin B6, 0.02 mg vitamin B12)
Trial: 24465438
Drug: n‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 fatty acids (600 mg eicosapentaenoic and docosahexaenoic acids in a 2:1 ratio)
Trial: 20664561
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (140 g/day)
Trial: 20664561
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (50 g/day)
Trial: 17978064
Drug: Oral azithromycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral azithromycin, 500 mg/day for 28 days
Trial: 17978064
Drug: Intramuscular meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular meglumine antimoniate, 10 mg Sb/kg/day for 28 days
Trial: 17978064
Drug: Intramuscular meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular meglumine antimoniate (for patients who failed azithromycin)
Trial: 14762036
Drug: Warfarin (adjusted-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (adjusted-dose, target INR 1.4-2.8)
Trial: 12649515
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg/d)
Trial: 14762036
Drug: Both LA
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both LA and aCL antibodies positivity
Trial: 11477460
Drug: Beta-carotene (8.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (8.2 mg)
Trial: 7831627
Drug: Theophylline (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (oral, twice daily doses, trough serum concentrations between 8.4 and 13.5 mg/l)
Trial: 7831627
Drug: Salbutamol (inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (inhalation of 800 micrograms)
Trial: 3241821
Drug: Aspirin 20
RxNorm normalized name: aspirin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 20 mg daily
Trial: 3241821
Drug: Aspirin 1000
RxNorm normalized name: aspirin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1000 mg daily
Trial: 24228447
Drug: 0.187% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.187% ropivacaine and fentanyl 3.2 microg x ml(‐1)
Trial: 24228447
Drug: 0.187% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.187% levobupivacaine and fentanyl 3.2 microg ml(‐1)
Trial: 18362823
Drug: Interview administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interview administration of FACT-G
Trial: 18362823
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of FACT-G
Trial: 19809337
Drug: Risperidone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (up to 6 mg/day)
Trial: 11558625
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin B12 (Tricortin 1000)
Trial: 9168442
Drug: Escalating doses
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of epirubicin
Trial: 9168442
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of epirubicin
Trial: 29320575
Drug: AZP-531 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZP-531 (3 mg for 50-70 kg and 4 mg for >70 kg body weight)
Trial: 23251870
Drug: Armodafinil 150
RxNorm normalized name: armodafinil 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 150 mg
Trial: 16974191
Drug: DHEA (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (200 mg/d)
Trial: 18606587
Drug: Netilmicin once
RxNorm normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netilmicin once daily (5 mg/kg/die)
Trial: 18606587
Drug: Netilmicin twice
RxNorm normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netilmicin twice daily (5 mg/kg/die)
Trial: 15681986
Drug: Relaxation breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation breathing exercise (30 minutes daily for 6 weeks)
Trial: 42425
Drug: Lorazepam 4
RxNorm normalized name: lorazepam 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 4 mg/70 kg
Trial: 31888707
Drug: Internet-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based Cognitive Behavioral Treatment (iCBT) added to treatment as usual (TAU)
Trial: 28291859
Drug: Two interforaminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two interforaminal Straumann implants (Regular Neck, 4.1 mm diameter, 8 mm length) loaded with Locator attachments transforming preexisting inferior conventional denture into an IOD.
Trial: 26296857
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (4.4 g daily for 1 month)
Trial: 19489491
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Omeprazole and Amoxicillin)
Trial: 16261464
Drug: Landiolol (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (loading dose of 125 microg kg(‐1) min(‐1) for 1 min followed by an infusion at 40 microg kg(‐1) min(‐1) for 4 min)
Trial: 9260344
Drug: No-treatment wait‐list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment wait‐list control
Trial: 3553281
Drug: Vinpocetine 10
RxNorm normalized name: vinpocetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine 10 mg three times a day for 30 days, then 5 mg three times a day for 60 days
Trial: 25972286
Drug: Fidaxomicin 200
RxNorm normalized name: fidaxomicin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fidaxomicin 200 mg
Trial: 22191245
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy alone
Trial: 19101237
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 1,000 ml/day of fluid intake, 120 mmol/day sodium, and 250 mg furosemide twice daily
Trial: 19101237
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 1,000 ml/day of fluid intake, 120 mmol/day sodium, and 125 mg furosemide twice daily
Trial: 19101237
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 1,000 ml/day fluid intake, 80 mmol/day sodium, and 250 mg furosemide twice daily
Trial: 19101237
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: 1,000 ml/day fluid intake, 80 mmol/day sodium, and 125 mg furosemide twice daily
Trial: 19101237
Drug: Group E:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group E: 2,000 ml/day fluid intake, 120 mmol/day sodium, and 250 mg furosemide twice daily
Trial: 19101237
Drug: Group F:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group F: 2,000 ml/day fluid intake, 120 mmol/day sodium, and 125 mg furosemide twice daily
Trial: 19101237
Drug: Group G:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G: 2,000 ml/day fluid intake, 80 mmol/day sodium, and 250 mg furosemide twice daily
Trial: 19101237
Drug: Group H:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group H: 2,000 ml/day fluid intake, 80 mmol/day sodium, and 125 mg furosemide twice daily
Trial: 15331895
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg intravenous Ketorolac
Trial: 7691114
Drug: G-CSF +
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF + quinolone
Trial: 23000049
Drug: Non-augmented group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-augmented group (fixed using LCP DF without augmentation)
Trial: 18211656
Drug: Structured pharmaceutical
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured pharmaceutical care service (including education and introduction of intensive self‐monitoring)
Trial: 16322118
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (50 mg daily) and methotrexate (2.5 mg twice daily on days 1 and 4)
Trial: 16322118
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (50 mg daily) and methotrexate (2.5 mg twice daily on days 1 and 4) plus thalidomide (200 mg daily)
Trial: 29020479
Drug: Topical silicone
RxNorm normalized name: silicones Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silicone gel applied after Er:YAG laser treatment
Trial: 29020479
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied after Er:YAG laser treatment
Trial: 26923831
Drug: Silicone intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone intranasal splints removed on the fifth postoperative day
Trial: 26923831
Drug: Silicone intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone intranasal splints removed on the seventh postoperative day
Trial: 26923831
Drug: Silicone intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone intranasal splints removed on the tenth postoperative day
Trial: 24786930
Drug: Resistive home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resistive home exercise (12 weeks, 5 days/week) followed by twice-a-week home or gym exercise (12 weeks)
Trial: 15037328
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily
Trial: 9840102
Drug: Topical glucocorticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glucocorticosteroids (hydrocortisone acetate foam preparation, 100 mg b.i.d.)
Trial: 1091216
Drug: Fluprednylidene acetate
RxNorm normalized name: fluprednidene
DrugBank: Fluprednidene acetate (DB14634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluprednylidene acetate cream applied once daily plus cream base of the same formulation twice daily
Trial: 1091216
Drug: Fluprednylidene acetate
RxNorm normalized name: fluprednidene
DrugBank: Fluprednidene acetate (DB14634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluprednylidene acetate cream applied 3 times daily
Trial: 1091216
Drug: Betamethasone 17-valerate
RxNorm normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone 17-valerate cream applied 3 times daily
Trial: 22884040
Drug: Infliximab treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab treatment group
Trial: 23563444
Drug: 2 hours
RxNorm normalized name: PATCH, TRANSDERMAL 72 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hours of daily patching with active vision therapy
Trial: 23563444
Drug: 2 hours
RxNorm normalized name: PATCH, TRANSDERMAL 72 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hours of daily patching with placebo vision therapy
Trial: 15559530
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor-based first line triple therapies
Trial: 15559530
Drug: H2 blockers-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 blockers-based therapies
Trial: 15559530
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor-based double combinations
Trial: 15559530
Drug: Clarithromycin+amoxicillin/nitroimidazole combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin+amoxicillin/nitroimidazole combinations
Trial: 15559530
Drug: Amoxicillin-nitroimidazole regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-nitroimidazole regimens
Trial: 15559530
Drug: Quadruple therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapies (first-line)
Trial: 15559530
Drug: Quadruple therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapies (second-line)
Trial: 11426363
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (30,000 KIU/kg added to pump prime, 15,000 KIU/kg every hour during cardiopulmonary bypass)
Trial: 7643542
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (AHT) - angiotensin converting enzyme inhibition for 6 (2 to 15) years
Trial: 30812036
Drug: No mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mechanical bowel preparation (MBP)
Trial: 30812036
Drug: Routine mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine mechanical bowel preparation (MBP)
Trial: 9585392
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors (ACEIs)
Trial: 18559556
Drug: Curcumin 10
RxNorm normalized name: curcumin 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 10 g
Trial: 18559556
Drug: Curcumin 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 12 g
Trial: 16176340
Drug: Landiolol (short‐acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (short‐acting beta‐1‐adrenergic blocker)
Trial: 2118879
Drug: Repeated application
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated application of the same dose
Trial: 23758661
Drug: 2 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 minutes of daily progressive resistance training with elastic tubing
Trial: 23758661
Drug: 12 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 minutes of daily progressive resistance training with elastic tubing
Trial: 23758661
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving weekly information on general health
Trial: 14985224
Drug: 400 micro
RxNorm normalized name: EM 2400 Micro Volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micro g folic acid
Trial: 14985224
Drug: 416 micro
RxNorm normalized name: Lipantil Micro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 416 micro g [6S]-5-MTHF
Trial: 14985224
Drug: 208 micro
RxNorm normalized name: Lipantil Micro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 208 micro g [6S]-5-MTHF
Trial: 11134430
Drug: Recombinant granulocyte
RxNorm normalized name: Glycosylated recombinant granulocyte colony stimulating factor
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant granulocyte colony-stimulating factor (rG-CSF) 10 microgram/kg/day IV once daily for 3 days
Trial: 8487664
Drug: HEPARIN
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HEPARIN
Trial: 24439136
Drug: Tigecycline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (150 mg once-daily)
Trial: 24439136
Drug: Ertapenem ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem ± vancomycin (1 g once-daily)
Trial: 19128258
Drug: Topical basic
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical basic fibroblast growth factor (bFGF)
Trial: 12525515
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus fluorouracil (FU)-leucovorin chemotherapy (431 patients)
Trial: 8780417
Drug: Desipramine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (200 mg daily)
Trial: 1363375
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of propranolol
Trial: 1363375
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of diazepam
Trial: 6469178
Drug: Maaloxan Suspension
RxNorm normalized name: alloxan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maaloxan Suspension
Trial: 6469178
Drug: Kompensan‐S forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kompensan‐S forte Suspension
Trial: 6469178
Drug: Solugastril 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solugastril 50 Gel
Trial: 29318917
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training (20-minute session) combined with manual therapy (15-minute session) and therapeutic exercise (15-minute session)
Trial: 27390979
Drug: Trimetazidine (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (35 mg tablet/twice daily for 4 days)
Trial: 19579590
Drug: Preoperative serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative serum levels of TPA (cut off level = 53 IU/L) after liver resection
Trial: 19579590
Drug: Preoperative serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative serum levels of TPS (cut off level = 81 IU/L) after liver resection
Trial: 17505265
Drug: Interferon alpha2b
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha2b 10 million units/m(2) subcutaneously three times a week plus rh-Endostatin 45 mg/m(2) subcutaneously every 12 h (arm A)
Trial: 15370023
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment in a specialist clinic
Trial: 15370023
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment in a shared care setting
Trial: 11462292
Drug: SonoVue (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue (0.3, 0.6, 1.2, and 2.4 mL intravenous bolus injection)
Trial: 9740292
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate at a dose of 20 mg/kg/day for 20 days (group A)
Trial: 9740292
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate at a dose of 20 mg/kg/day for 30 days (group B)
Trial: 27044854
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 70 mg/kg
Trial: 23986157
Drug: 6% salicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% salicylic acid cream
Trial: 18754533
Drug: Low power
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low power laser (LPL) therapy (9‐11 joules/cm2) over the carpal tunnel area
Trial: 12911781
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) with Alutard(R)‐SQ, Dermatophagoides pteronyssinus extract, administered with increasing doses until maintenance dose reached, then once a month for 12 months.
Trial: 12911781
Drug: Placebo preparation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo preparation, identical to the active preparation.
Trial: 10575594
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ipriflavone orally daily
Trial: 10575594
Drug: 20 units
RxNorm normalized name: Omnipod GO 20 Units/Day Pods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 units elcatonin, weekly injected intramuscularly
Trial: 8767354
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg effervescent tablet